BenevolentAI Investor Day Presentation Deck | Slidebook.io

BenevolentAI Investor Day Presentation Deck

September 2022, 74 slides

analyst investor event in drug discovery interim results for months ended june invest benevolent | BenevolentAI

disclaimer forward looking statements this document may contain forward looking statements forward looking statements are statements that are not historical facts and may be by words such as plans targets aims believes expects anticipates intends estimates will may should and similar expressions forward looking statements include statements regarding objectives goals strategies outlook and growth prospects future plans events or performance and potential for future growth economic outlook and industry trends developments in markets the impact of regulatory initiatives and or the strength of competitors these forward looking statements at the time made beliefs intentions and current targets aims forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future the forward looking statements in this release are based upon various assumptions based on without limitation management examination of historical operating trends data contained in records and third party data although believes that these assumptions were reasonable when made these assumptions are inherently subject to cant known and unknown risks uncertainties contingencies and other important factors which are cult or impossible to predict and are beyond control forward looking statements are not guarantees of future performance and such risks uncertainties contingencies and other important factors could cause the actual outcomes and the results of operations condition and liquidity of or the industry to differ materially from those results expressed or implied by such forward looking statements the forward looking statements speak only as of the date of this release no representation or warranty is made that any of these forward looking statements or forecasts will come to pass or that any forecast result will be achieved | BenevolentAI

opening remarks introduction shields benevolent | BenevolentAI

clinical stage enabled drug discovery company uniting intelligence with cutting edge science to decipher complex disease biology and discover novel treatments benevolent | BenevolentAI

the benevolent platform is and commercially validated and has already delivered asset in phase assets in exploratory stage programmes a leading covid treatment that is now approved successful target collaboration with further validates our approach with a total of novel targets selected for portfolio well funded with key value in points in the near and medium term scientifically | BenevolentAI

huge burden on society demands a new approach years gaining a clear understanding of the underlying molecular mechanisms of disease based on the totality of available data is a vital step in the development of successful and treatments | BenevolentAI

unprecedented opportunity to fundamentally rethink drug discovery the exponential growth in the production and availability of data combined with advances in and machine learning create the unprecedented opportunity to rethink the drug discovery and development process | BenevolentAI

the benevolent platform a versatile scalable and proven enabled engine diverse data sources the benevolent disease agnostic modality agnostic enables novel target accelerates discovery scalable and repeatable potential to increase probability of success enabled | BenevolentAI

about us in platform investment board with deep across drug discovery development pharmaceuticals listed on cash runway to providing capital for key value in points team board | BenevolentAI

market context enabled drug discovery the business model our approach and technology drug discovery and pipeline review interim results review closing remarks outlook a | BenevolentAI

market context enabled drug discovery coo and founder enabled benevolent | BenevolentAI

is becoming a validated approach in cant investment fuels massive growth for the market in drug discovery development drug discovery companies internal pipelines this progress has been underpinned by three trends advances in machine learning techniques greater availability of data increase in computational power | BenevolentAI

the value proposition for direct cost savings increasing probability of success faster and cost effective get it right more often over years over years reduce clinical cost by and time to market by years highest attrition is at phase current success rate phase trial failures due to lack of | BenevolentAI

of companies in hit target companies can be characterized across two key dimensions original technology focus and drug discovery approach target hit hypothesis driven non hypothesis driven figure analysis listed companies only companies also active in the space through internal development and or collaborations companies also active in the space through internal development and or collaborations | BenevolentAI

technology approach our data foundations integrate the world relevant and available data to surface insights through our tools improving how scientists discover and develop new therapies creating data foundations tools for scientists | BenevolentAI

principles and bene of our technology approach industry challenges half of clinical failures due to poor understanding of disease biology mechanisms disease approach scientists can connect or infer shared mechanisms across diseases single modality data each with limitations and biases often limited understanding of what drives lab phenotypic effects much of target discovery is not a scalable or repeatable process approach biology comprehensive data approach hypothesis driven based benefits disease agnostic modality agnostic enables novel target accelerates discovery scalable repeatable potential to increase probability of success | BenevolentAI

how approach compares to industry typical proportion of targets validated by lab assay potential increase in chance of a drug reaching the market industry time from target to candidate yrs potential time saved relative to industry at least yrs cost from target to potential cost bene per relative to industry saving | BenevolentAI

what that equates to higher productivity number of new led by year by and companies median number of phase i starts over years | BenevolentAI

the business model coo and founder benevolent | BenevolentAI

in house pipeline the business model leveraging our technology platform to generate new drug at scale decision criteria develop in house out license at end phase i or end phase milestones royalties collaborations selective platform collaborations which can leverage the platform in areas outside our core competencies economic bene platform validation data generated enriches the benevolent non commercial collaborations covid platform validation data generated enriches the benevolent | BenevolentAI

therapy area and business model rationale competitive commercial scientific commercial clinical development data core therapeutic areas clinical development development out license at phase i or phase scientific strategy out license prior to phase i non core therapeutic areas collaborations non commercial collaborations | BenevolentAI

benevolent a validated approach internal pipeline validation strategic validation clinical regulatory validation pipeline generated from the benevolent platform one asset in phase assets in and named platform generated drug programmes exploratory stage programmes successful delivery on target long term collaboration us drug approved the benevolent successfully discovered an approved treatment for covid chronic kidney disease disease agnostic idiopathic pulmonary heart failure systemic lupus | BenevolentAI

internal validation pipeline generated from the benevolent platform | BenevolentAI

strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph and teams working in close collaboration to explore identify and validate targets therapeutic areas initial deal expansion key milestones deal structure of license fee milestone payments and downstream royalties to date three novel targets have been validated selected for portfolio collaboration enables to enrich its platform via the data generated as part of the collaboration but also further validate the use of our platform may | BenevolentAI

regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI

animated benevolent platform video director of engineering | BenevolentAI

the approach our technology benevolent | BenevolentAI

the benevolent platform data foundations and tools our data foundations integrate the world relevant and available data to surface insights through our tools improving how scientists discover and develop new therapies data foundations tools for scientists | BenevolentAI

data foundations integrate diverse data types data foundations the data foundation of our platform integrates disparate data sources a data foundation that is proprietary and scalable | BenevolentAI

the data foundations in numbers data foundations data modalities data volume ontology and dictionary genetics and clinical experimental literature structured derived total proprietary data sources relationships entity types proprietary information | BenevolentAI

data modalities paired with processing pipelines literature processing pipeline data foundations precision medicine genetics processing pipeline | BenevolentAI

the benevolent platform data foundations and tools our data foundations integrate the world relevant and available data to surface insights through our tools improving how scientists discover and develop new therapies target data foundations tools for scientists | BenevolentAI

target work and tools target | BenevolentAI

target discovery tools and process promising novel therapeutic targets target target prediction can we treat als by reversing autophagy impairment in microglia by reducing oxidative stress the tech approach triage and assess targets validate experimentally identifies | BenevolentAI

the tech approach by exploring the data target define | BenevolentAI

triage targets to select only the most promising hypotheses target view from the triage tool | BenevolentAI

target assessment identify the hypotheses most likely to succeed target view from target assessment tool | BenevolentAI

bene from our technology approach disease agnostic modality agnostic novel target accelerates discovery scalable repeatable potential to increase probability of success benefits | BenevolentAI

drug discovery pipeline review benevolent | BenevolentAI

advanced laboratory capabilities help move programmes faster and generate data at scale for continuous innovation advanced capabilities and technologies experimental capabilities enhance entire drug discovery process closing the data loop work progresses rapidly from in silico to in experimental test dynamic experimental feedback loop between scientists technologists | BenevolentAI

internal validation pipeline generated from the benevolent platform highlights | BenevolentAI

ben atopic dermatitis atopic dermatitis is the most common chronic in skin disease characterized by intensely itchy red and swollen skin affects of children and up to of adults approximately of all cases present with mild moderate disease severity prevalence is rising with market value in forecast to exceed billion skin in and chronic pruritus associated with atopic dermatitis negatively impact quality of life and psychosocial well being clear unmet need in mild to moderate patient segment for treatment addressing itch and in without side effects of steroids | BenevolentAI

ben a potent antagonist developed to relieve in and provide rapid itch resolution atopic dermatitis ben is a inhibitor targeting and receptors the receptors were as part of an effort to mediators of both itch and in in using our molecular design we were able to design a inhibitor equipotent against the receptors ben is expected to treat atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization in addition to inhibiting and mediated dermal in ben will target mild moderate and severe atopic dermatitis patients addressing unmet need in the treatment of mild to moderate atopic dermatitis as a steroid sparing alternative and in more severe patients undergoing treatment with that require add on treatment | BenevolentAI

atopic dermatitis ben rationale potentiates stimulated cell in responses and synergistically enhances cell receptor induced production by cells mast cells within skin lesions express high levels of compared to normal controls skin resident express elevated levels of together with and and functionally respond to inhibit and increase chemotactic index levels in skin dramatically increase in response to in stimuli produced by is a major mediator of cutaneous increased in the skin sensitizes primary afferents contributing to peripheral itch sensitization and chronic pruritus involved in the in activation of mast cells and | BenevolentAI

we expect ben to provide both symptomatic relief and to reverse disease progression in atopic dermatitis ben is highly selective for receptors with potencies in the low range for and ben dose dependently inhibits release of in and and in human peripheral blood mononuclear cells stimulated with an in cell stimulus anti ben inhibition of human primary cell activation ben inhibits the release of gene related peptide a mediator of itch sensory nerve and neurogenic in in dorsal root ganglion isolated from adult rats and stimulated with ben series reduced mouse ear in following administration of reducing expression of and ben demonstrates excellent tolerability and safety margins in enabling toxicology studies inhibition of sensory neuron activation reduction in mouse ear in | BenevolentAI

ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI

ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI

ben indicative data from phase eczema area and severity index caveats phase was not powered to meaningfully assess only patients dosed with active per group maximum duration of dosing days score changes typically measured at days | BenevolentAI

ben phase progressing phase double blind placebo controlled in patient two part clinical study day day day day active recruiting sites in the in a further sites under approval recruitment completion anticipated our intention is to to partner this asset with a pharmaceutical company that has a focus in dermatology for continued clinical development and if approved our intention is to out development and of ben following completion of this trial with key big and dermatology specialists as potential part | BenevolentAI

ben is being developed to address key unmet needs in the treatment of atopic dermatitis atopic dermatitis treatment paradigm ben development is targeting against both itch and in with potential disease modifying effects improved safety pro suitable for chronic use with no irritancy on application positioning potential to displace ineffective and poorly tolerated second line treatment for chronic use in adults and potential use in a subset of line patients where rapid itch resolution is key and in the severe patient population as an adjunct treatment option | BenevolentAI

professor of immunology and the school of medicine and dentistry interests mucosal immunology and in in man | BenevolentAI

ulcerative colitis affects us population million patients in forecast market by experimental model system in colonic mucosa biopsies from patients | BenevolentAI

experimental model system in colonic mucosa biopsies from patients | BenevolentAI

colon biopsy signatures | BenevolentAI

and biopsies responsive to pharmacological intervention | BenevolentAI

target cation work can we treat by reversing chronic in of the colonic mucosa by targeting pathways in colon epithelial cells and tissue resident immune cells experimental validation identification | BenevolentAI

ben a novel target for data support the rationale for as a novel target for regulates signal transduction by is in derived colon and colonic mucosa samples whilst which makes is down regulated reduced levels of correlate with increased in colonic mucosa is in and its expression inversely correlates to disease severity is well studied in disorders but not in in with zero linkage to demonstrates restricted expression in peripheral tissue reduces the safety liability of targeted inhibition | BenevolentAI

target validation in colon tissue from ulcerative colitis patients in colonic mucosa biopsies from patients disease phenotype retained with high basal release and key mediators of pathology tissue samples treated with target selective tool compound ben positive controls and selective target inhibition showed comparable reduction of and to the positive controls validated as a target with a novel mechanism of action for ulcerative colitis | BenevolentAI

inhibition potential to mechanisms in inhibition camp reduced in release from intestinal epithelia via reduced tissue resident macrophage activation improved assembly via mediated improved mucus homeostasis via phosphorylation of intestinal reduced intestinal in improved barrier integrity | BenevolentAI

ben results and progress to date novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in only years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI

ben best in class oral peripherally restricted potent and selective drug for the treatment of moderate severe an opportunity to differentiate on safety and a precision medicine approaches safety | BenevolentAI

internal pipeline continued progress progress in several programmes have progressed through key stage gates candidate nominated enabling studies to begin als asset transitioned through to candidate seeking oncology programmes transitioned into lead new portfolio entrant for disease | BenevolentAI

our precision medicine approaches are applied to multiple stages of our pipeline and can support activities precision medicine enabled target indication mapping additional indications a target or drug approved or in development through the cation of additional disease indications address additional unmet need the value of a target or drug identifying key patient cohorts and responders for drugs clinical development increase probability of success improve outcomes for patients cation of patient cohorts responders trial design patient outcomes for each indication | BenevolentAI

portfolio key in points ben atopic dermatitis ben ulcerative colitis ben pipeline depth and progression inflection | BenevolentAI

interim results operational financial review months ended june nick benevolent | BenevolentAI

highlights continued progress across in house pipeline consistent delivery in collaboration with non commercial collaborations progressing full approval of covid treatment by continuous enhancement of the benevolent platform completed business combination listed raised gross proceeds of strengthened board of directors and leadership building business operations capability for long term success | BenevolentAI

financial highlights revenue increase across collaboration with a milestone reached related to the second novel target for idiopathic pulmonary spend increase driven by portfolio advancing into later stages of development in particular ben entering adaptive phase i clinical study spend increase increased which is set to plateau bus spend driven predominantly by listing status but expected to maintain at this level | BenevolentAI

walk from reported to reported loss driven by non recurring costs of business combination non cash exceptional costs related to acceleration of share based payments also incurred from business combination and set to reduce beyond non cash listing service expenses cost of share issuance to as part of business combination net of assets acquired before pipe and backstop | BenevolentAI

cash focused upon drug and platform development lab equipment computer property related leases charge from holdings gain from operational non transaction related equity awards removed from the no cash impact largely driven by outstanding tax credit receivable expected in and other payable decreases end june cash position of provides ample liquidity to meet multiple key value in points | BenevolentAI

cash runway to providing capital for key value in points sufficient inflection | BenevolentAI

closing remarks and outlook shields benevolent | BenevolentAI

investment highlights market leader in drug discovery with and technologically differentiated approach robust with patents on drug pipeline and copyright and trade secrets on our technology platform cant platform scale and internal capability flexible business model with revenue opportunities to extend cash runway rich portfolio of drug programmes all generated from the benevolent platform near and medium term key value in points high value and successful commercial partnership proving strategic validation world renowned board and experienced leadership team | BenevolentAI

poised for growth and success strengthened position enhances our leadership position in enabled drug discovery and enable us to independently pursue the clinical development of certain in house pipeline assets in core therapeutic areas out license multiple assets over the next years to strengthen our balance sheet and drive long term value creation increase the size of our pipeline with a healthy balance of new in class and best in class assets with stage drug candidates every year sign new collaboration agreements with companies to to leverage our disease agnostic capabilities into therapeutic indications outside our focus areas to generate incremental revenue maintain our leading position in target through increased investment in our technology capabilities build out our technology metrics to exemplify the differentiation of our approach | BenevolentAI

benevolent benevolent investors benevolent | BenevolentAI

See More

BenevolentAI

Investor Day Presentation Decks

Biotechnology Decks

Healthcare Decks

Explore Topics

Drug discovery

Clinical development

Drug candidate

Recent decks by BenevolentAI

Results

March 2024

Investor Conference

January 2024

Investor Presentation

May 2023

Results

March 2023

See all presentations by BenevolentAI (10 decks)

Related decks

Exscientia

Investor Presentation

March 2024

Absci

Investor Presentation

July 2023

AbCellera

Investor Conference

May 2022

Bionomics

IPO

December 2021

Absci

Investor Presentation

May 2022

Absci

Investor Presentation

October 2023

Absci

Investor Conference

January 2023

Absci

Investor Presentation

October 2022

Recent decks by BenevolentAI

See all presentations (10 decks)

Results

March 2024

Investor Conference

January 2024

Investor Presentation

May 2023

Results

March 2023

Related decks

Exscientia

Investor Presentation

March 2024

Absci

Investor Presentation

July 2023

AbCellera

Investor Conference

May 2022

Bionomics

IPO

December 2021

Absci

Investor Presentation

May 2022

Absci

Investor Presentation

October 2023

Absci

Investor Conference

January 2023

Absci

Investor Presentation

October 2022

Search Thousands of Presentations by World Leading Companies

Trending:

Addressable Market

Management Team

Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Investment Banking

Explore

Presentation Collections

Slide Collections

Company

© 2021-2023 Slidebook.io